Table 1.
Characteristic | N (%) |
---|---|
Age (median) | 54.5 (29-70) |
Age Group: | |
<40 | 4 (13) |
40-49 | 7 (23) |
50-59 | 9 (30) |
≥ 60 | 10 (16) |
Race: | |
White | 29 (97) |
Other | 1 (3) |
Menopausal Status: | |
Pre-menopausal | 10 (33) |
Post-menopausal | 20 (67) |
ER/PR Status: | |
ER or PR Positive | 20 (67) |
ER and PR Negative | 10 (33) |
Previous Breast Surgery: | |
Breast Conserving | 7 (23) |
Mastectomy | 23 (77) |
Nodal Status: | |
Node Positive (1-3+ nodes) | 9 (30) |
Node Positive (4-9+ nodes) | 1 (3) |
Node Positive (10+ nodes) | 3 (10) |
Node Negative | 17 (57) |
Nottingham Tumor Grade: | |
Well /Intermediate | 7 (23) |
Poor | 23 (77) |
Histology: | |
InvasiveDuctal | 26 (87) |
InvasiveLobular | 4 (13) |
Size (cm) | |
<1 | 1 (3) |
1-2 | 11 (37) |
2-5 | 13 (43) |
> 5 | 5 (17) |
Side of Tumor | |
Left | 15 (50) |
Right | 15 (50) |
Performance Score | |
0 | 21 (70) |
1 | 9 (30) |
Smoking Status | |
Never | 20 (67) |
Current | 4 (13) |
Former | 6 (20) |
History of Diseases: | |
Diabetes | 2 (7) |
Hypertension | 9 (30) |
Other | 9 (30) |
None | 20 (67) |
Any Prior Cancer | |
Yes | 1 (3) |
No | 29 (97) |
Planned Hormone Therapy | |
Tamoxifen | 6 (20) |
Aromatase Inhibitor | 10 (33) |
None | 14 (47) |
Planned Radiation Therapy | |
Yes | 14 (47) |
No | 16 (53) |